omniture
logo
Search
和铂医药（上海）有限公司 Harbour BioMed
Media Room

Latest News

rss

HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering

This press release is NOT for release, publication, distribution, directly or indirectly, in or int...

2020-12-09 17:29 6219

Harbour BioMed Will Present Results From Its Phase II Clinical Trial with Tanfanercept (HBM9036) in Patients with Moderate-to-Severe Dry Eye Disease in China at the 25th Congress of Chinese Ophthalmological Society

SUZHOU, China, Nov. 16, 2020 /PRNewswire/ -- Harbour BioMed (HBM), a global, clinical-stage, bio-ph...

2020-11-16 20:17 3188

Harbour BioMed Announces Dosing of First Patients in Two Phase II Clinical Studies of Batoclimab (HBM9161) for the Treatment of Myasthenia Gravis and Immune Thrombocytopenia

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 30, 2020 /PRNewswire/ -- Harbo...

2020-09-30 21:50 5463

Harbour BioMed Announces Two China NMPA Clearances for Clinical Trials for Phase I & Combination Therapy of Next Generation Anti-CTLA-4 Antibody for Treatment of Solid Tumors

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Sept. 21, 2020 /PRNewswire/ -- Harbo...

2020-09-21 20:12 3997

Harbour BioMed and Hualan Genetic Announced Collaboration to Develop Multiple Innovative Antibody Programs

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, SUZHOU,China and XINXIANG, China, Sept. 11, 2020 /PRNewsw...

2020-09-11 21:33 7624

Harbour BioMed Presented Its Newly Discovered Anti-Human CCR8 Novel Monoclonal Antibodies at the 16th PEGS Boston 2020

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, Sept. 2, 2020 /PRNewswire/ -- Harbour Bi...

2020-09-02 11:40 3888

Harbour BioMed Will Present Its New Platform HBICE (Heavy chain only antibody (HCAb) Based Immune Cell Engager) at 16th PEGS Boston Summit

SHANGHAI, Aug. 31, 2020 /PRNewswire/ -- Harbour BioMed, a global, clinical-stage, innovative biopha...

2020-08-31 21:39 4434

Harbour BioMed Signs Strategic Collaboration Agreement with Vir Biotechnology to Develop Novel Therapies for Immuno-Oncology and Infectious Diseases

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 24, 2020 /PRNewswire/ -- Harbou...

2020-08-24 19:00 3594

Harbour BioMed Presented Its Newly Discovered BCMA x CD3 Bispecific Antibody at Cell Engager Summit 2020

CAMBRIDGE, Mass., ROTTERDAM, Netherlands, and SUZHOU, China, Aug. 21, 2020 /PRNewswire/ -- Harbour ...

2020-08-21 21:31 7336

Harbour BioMed, Utrecht University, Erasmus Medical Center, Viroclinics-DDL and Kiadis Pharma Announce Collaboration to Develop Monoclonal Antibody, Natural Killer Cell Combination Approach to Treating COVID-19

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Aug. 19, 2020 /PRNewswire/ -- Harbou...

2020-08-19 19:43 3190

Harbour BioMed Announces Strategic Partnership with Viva Biotech to Collaborate on Incubating Innovative Biotech Start-ups

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, SHANGHAI, China, July 31, 2020 /PRNewswire/...

2020-07-31 08:56 5485

Harbour BioMed Presented Pre-Clinical Data on A Fully Human Anti-CD73 Antibody at AACR Virtual Annual Meeting

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI, July 16, 2020 /PRNewswire/ -- Harbour Bi...

2020-07-16 18:00 4211

Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board

CAMBRIDGE, Mass, ROTTERDAM, Netherlands...

2020-06-11 18:00 4552
Harbour BioMed Appoints Dr. Jon Wigginton to its Scientific Advisory Board

Harbour BioMed Announces First Patient Dosing of Phase 1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder

* First anti-FcRn PoC study for the treatment of NMOSD * Anti-FcRn antibody with potential to be...

2020-04-21 17:00 3218
12345